Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-92480 PK and PPI Interaction Study in Healthy Volunteers
NCT04211545Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mezigdomide in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Area Under the Curve from Time Zero to Infinity up to 5 days. Started Oct 2019; status: completed.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04211545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211545.